Drug intelligence / Profile preview

DSP-8658

Development stage: Phase 1
Lead developer: Sumitomo Pharma
Modality: Small Molecules
Administration: Oral

Overview

DSP-8658 is a novel selective peroxisome proliferator-activated receptor alpha/gamma (PPARα/γ) modulator. It is primarily being developed for the treatment of Type 2 Diabetes Mellitus. Unlike PPARγ full agonists, DSP-8658 improves blood glucose levels without increasing adipogenesis in diabetic obese mice. Additionally, it has shown potential in enhancing microglial amyloid-β phagocytosis, which could be beneficial in Alzheimer's disease treatment.

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on DSP-8658.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DSP-8658.

Explore the full profile